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A nosocomial outbreak of disease involving 5 patients, 
4 of whom died, occurred in South Africa during September–
October 2008. The first patient had been transferred from 
Zambia  to  South Africa  for  medical  management.  Three 
cases involved secondary spread of infection from the first 
patient, and 1 was a tertiary infection. A novel arenavirus 
was identified. The source of the first patient’s infection re-
mains undetermined.
A
renaviruses associated with rodents are known to cause 
fatal hemorrhagic fevers in humans in South America 
and West Africa. We describe a nosocomial outbreak of 
infection with a novel arenavirus involving 5 patients, 4 of 
whom died, which occurred in South Africa in September–
October 2008. The first patient was transferred from Zam-
bia to South Africa for medical management. The source of 
her infection remains undetermined. Three cases involved 
secondary spread of infection from the first patient, and 1 
tertiary infection occurred. 
The Outbreak 
Patient 1 (Figure 1) was a travel agent who lived on an 
agricultural smallholding on the outskirts of Lusaka, Zam-
bia, where she kept horses, dogs, and cats. She occasionally 
encountered dormice in her home, and evidence of rodent 
activity was found in the stables. She had visited a tourist 
camp on the Zambezi River on July 30 and 31, 2008, and 
participated in a polocrosse tournament on August 1 and 2 
(but neither event occurred within the known incubation 
period of arenavirus infections from the date of onset of her 
illness). On August 30, she was cut on the shin by broken 
glass from a dropped bottle. Severe headache and malaise 
developed in the patient on September 2. On September 4, 
she traveled by air to attend a wedding in South Africa and 
was taking medication for suspected influenza. Diarrhea 
and vomiting developed in 4 of 110 guests who attended 
the wedding on September 6. Patient 1 was not affected, 
but she reported feeling cold and took breaks from dancing 
to warm herself at a fireplace. On returning to Lusaka on 
September 7, she was exhausted and experienced an attack 
of diarrhea and vomiting.
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She remained ill in bed on September 8. The follow-
ing day she had fever, severe chest pain, and sore throat 
and was treated for food poisoning and influenza with an-
tiemetic, antipyretic, and analgesic medications and a ce-
phalosporin antimicrobial drug. On September 10, she felt 
slightly better, but overnight a rash developed that extend-
ed from her toes to her cheeks, as did severe myalgia and 
facial swelling. She was treated at a clinic on September 11 
for a presumed allergic reaction to the cephalosporin, was 
discharged, and then readmitted that evening with severe 
sore throat. She was moved to a hospital for stabilization 
on September 12 and then evacuated by air to South Africa. 
During the flight, the attending physician and paramedic 
were potentially exposed to infection through nebulization, 
suctioning, and manual ventilation of the patient.
When she arrived at a private hospital in Johannesburg, 
her  pupillary  and  corneal  reflexes  were  absent,  and  she 
had cerebral edema (confirmed by computed tomography 
scan), acute respiratory distress syndrome, and deteriorat-
ing renal function. She had thrombocytopenia, granulocy-
tosis, and raised serum alanine and aspartate transaminase 
levels. The observation of an apparent eschar on her right 
foot prompted treatment for rickettsiosis. Despite intensive 
care, including hemodialysis, she died on September 14. 
No autopsy was performed, and the body was returned to 
Zambia for cremation.
Patient 2 (Figure 1) was the paramedic who attended 
patient 1 during the air evacuation to Johannesburg. He had 
onset of illness on September 21 with headache, myalgia, 
and fever, and on September 24 he was admitted to a hos-
pital in Lusaka. On September 27, he was evacuated to the 
same hospital in Johannesburg as patient 1, and on the fol-
lowing day the link between the 2 was identified and a pre-
sumptive diagnosis of viral hemorrhagic fever was made. 
Patient 2 died October 2. Tracing of contacts of the 2 pa-
tients was instituted, and it was found that a nurse, patient 
3 (Figure 1), who had attended and cleaned the body of 
patient 1, became ill on September 23 while on leave. She 
was admitted to a private hospital west of Johannesburg on 
October 1, where she died October 5.
Blood samples were collected from patient 2 on Sep-
tember 29 and 30 and from patient 3 on October 3.  The 
samples were screened at the National Institute for Com-
municable Diseases (NICD) for evidence of infection with 
known agents of the viral hemorrhagic fevers of Africa by 
reverse transcription–PCR (RT-PCR) for presence of viral 
nucleic acid, including 2 procedures with primers designed 
to detect all known Old World arenaviruses (1,2). Samples 
were also tested by ELISA for antibodies, without posi-
tive results, and injected into Vero cell cultures for isola-
tion of virus. For administrative reasons, the taking of liver 
samples with biopsy needles and the taking of skin punch 
samples from the bodies of patients 2 and 3 was delayed 
until October 9, and by the next morning the Department 
of Anatomical Pathology at the University of the Witwa-
tersrand reported observing hepatocyte necrosis and skin 
vasculitis compatible with viral hemorrhagic fever (Figure 
2, panel A).
Diagnosis and Contact Tracing 
Blood, liver, and skin samples sent to the Centers for 
Disease Control and Prevention (CDC; Atlanta, GA, USA) 
arrived on October 10. The following day the Infectious 
Disease Pathology Branch reported that immunohistochem-
ical staining of liver and skin sections resulted in the detec-
tion of antigen with monoclonal antibody that was broadly 
cross-reactive for Old World arenaviruses, the first indica-
tion of an etiologic diagnosis (Figure 2, panel B). Conse-
quently, the same arenavirus RT-PCR procedures as above 
were applied to liver extracts and produced positive results 
at NICD and the Special Pathogens Branch, CDC. One RT-
PCR procedure yielded ≈300-bp glycoprotein gene product 
(1), and the other yielded ≈1,000-bp nucleoprotein gene 
product (2). Nucleotide sequencing of the PCR products 
and phylogenetic analysis performed as described (3) but 
using MEGA 4.0 (4) showed that a novel arenavirus, since 
named Lujo virus (5), was involved (Figure 3).
Replicate  nucleic  acid  extracts  from  liver  samples 
that were sent to Columbia University (New York, NY, 
USA) were subjected to 454 pyrosequencing to produce 
full-length genome sequences of the arenavirus, extending 
the preliminary findings based on partial sequence data to 
indicate that the new virus is related to, but distinct from, 
known Old World arenaviruses (5). The novel arenavirus 
was isolated in culture from the blood and liver samples of 
patients 2 and 3, as confirmed by immunofluorescence with 
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Figure  1.  Epidemic  curve  showing,  as  appropriate,  dates  of 
exposure to infection, onset of illness, admission to hospital, and 
death or recovery of 5 patients involved in an outbreak of infection 
with a novel arenavirus, southern Africa, 2008.
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polyvalent Old World arenavirus antiserum and sequenc-
ing of PCR products. However, the isolates from the blood 
samples took a minimum of 7 days to become detectable in 
culture, as compared with 3–5 days for liver samples and 
other blood samples tested during the investigation. Thus, 
it can be surmised that the viral loads were likely too low in 
the blood samples of patients 2 and 3 for detection of viral 
nucleic acid with the generic primers.
Through contact tracing, we found that a cleaner who 
worked at the hospital where patient 1 was treated, patient 
4 (Figure 1), became ill on September 27, was admitted to 
a provincial hospital on October 5, and was transferred the 
same day to a tertiary academic hospital. She had a chronic 
underlying disease and died on the day after admission. Her 
only potential exposure to infection occurred September 14 
when she cleaned the cubicle where patient 1 was treated. 
On October 9, a second nurse, patient 5 (Figure 1) became 
sick and was admitted to the hospital the following day. 
She had attended patient 2 and been involved in the inser-
tion of a central venous line on September 27 before barrier 
nursing was instituted.
Treatment of patient 5 with the oral form of the antivi-
ral drug ribavirin was started on October 11 with a loading 
dose of 30 mg/kg (2 g), followed by a projected schedule of 
15 mg/kg every 6 h (1 g) for 4 days and 7.5 mg/kg every 8 h 
for 6 days. However, after the patient was intubated on Oc-
tober 12, treatment was continued through nasogastric tube 
until the intravenous formulation of the drug was obtained 
on October 17 (6). The patient reported improvement be-
ginning October 27 and was discharged from the hospital 
on December 2 after RT-PCR did not detect viral RNA in 
blood and urine on 3 consecutive occasions.
The  first  4  patients  were  initially  managed  without 
special infection control precautions, apart from the don-
ning of surgical gloves for intubation or the taking of blood 
samples, and the use of impervious aprons in wards. Con-
sequently, healthcare workers and maintenance staff such 
as cleaners were all potentially exposed to contaminated 
bedding, eating utensils, and bedpans which contained ex-
creta and vomitus. On the other hand, no incidents occurred 
that could be construed as constituting specific exposure 
to infection, for example, needlesticks. After the possible 
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Figure  2.  Liver  biopsy  specimen  from  patient  2  showing  focal 
hepatocyte necrosis (arrows) without prominent inflammatory cell 
infiltrates (A) and Lujo virus antigens (red) distributed predominantly 
in  a  membranous  pattern  around  infected  hepatocytes  (B). 
Hematoxylin  and  eosin  staining  in  panel A  and  immunoalkaline 
phosphatase staining with naphthol fast-red stain and monoclonal 
antibody  against  GP2  Lassa  virus  diluted  1:1,000  in  panel  B. 
Original magnifications ×50 (A) and ×100 (B).
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Figure 3. Neighbor-joining tree reconstructed by using bootstrap 
analysis  with  1,000  pseudoreplicate  datasets  showing  the 
phylogenetic  relationship  of  known  arenaviruses  (data  derived 
from GenBank) to the novel Lujo arenavirus from southern Africa 
(boldface),  inferred  from  a  619-nt  region  of  the  5′  end  of  the 
nucleoprotein gene. GenBank accession numbers for nucleotide 
sequence  data  are  shown  on  the  tree.  Scale  bar  indicates  5% 
divergence.Nosocomial Outbreak of Arenavirus Infection 
involvement of a viral hemorrhagic fever was recognized 
on September 28 following the admission of patient 2 to the 
hospital in Johannesburg, barrier nursing procedures were 
instituted as successive patients were identified, but only 
patient 5 was managed with full precautions throughout 
her illness. The full precautions consisted of the donning 
of double surgical gloves, protective oversuits, impervious 
overshoes, disposable balaclavas, and N95 masks plus gog-
gles or visors. Alternatively, the protective oversuits were 
replaced with surgical scrub-suits and impervious dispos-
able gowns. No infections appeared to have occurred after 
the adoption of the full precautions.
The  putative  incubation  periods  for  patients  2  to  5 
ranged from 7 to 13 days, and the periods of illness for the 
4 patients with fatal infections ranged from 10 to 13 days 
(Figure 1). All patients sought treatment for nonspecific fe-
brile illness with headache and myalgia, which increased 
in severity over 7 days with the development of diarrhea 
and pharyngitis. A morbilliform rash became evident on 
the face and trunk in 3 Caucasian patients on day 6–8 of 
illness, but not in 2 African patients, and neck and facial 
swelling  occurred  in  3  patients.  Four  patients  exhibited 
transient subjective improvement after ≈1 week of illness; 
this brief improvement was followed by rapid deterioration 
with respiratory distress, neurologic signs, and circulatory 
collapse, the terminal features in patients who died. Bleed-
ing was not a prominent feature. However, 1 patient had a 
petechial rash, 1 had gingival bleeding, and another expe-
rienced the oozing of blood from venipuncture sites. Chest 
pain was a prominent symptom for 2 patients. All patients 
had thrombocytopenia on admission to the hospital (plate-
let count range 20–104 × 109 cells/L). Three patients had 
leukocyte counts in the normal range, and 2 had leukopenia 
on admission, whereas leukocytosis developed in 4 patients 
during the illness. The maximum aspartate aminotransferase 
values recorded in the 4 patients who died from the disease 
ranged from 549 IU/L to 2,486 IU/L, compared with 240 
IU/L in the survivor who was treated with ribavirin.
Blood samples from patients 4 and 5 were positive by 
RT-PCR for arenavirus nucleic acid at NICD and yielded 
virus in culture. Blood samples taken from patient 1 on Sep-
tember 12 and from patient 2 on September 25 were traced 
to a hospital laboratory in Lusaka and sent to CDC late in 
the course of the investigation. The sample from patient 1 
was RT-PCR positive, and both samples yielded isolates 
of the novel virus in cell culture. In summary, isolation of 
virus was achieved from the blood samples of all 5 patients, 
plus liver samples from patients 2 and 3, at NICD, CDC, or 
both (Table).
Tracing and monitoring of all contacts of known pa-
tients for 21 days from last date of contact with a patient or 
fomites in Zambia and South Africa failed to identify cases 
additional to those reported here. Antibody surveys still 
need to be conducted to assess the occurrence of less severe 
infections and to determine the distribution and prevalence 
of the virus. Rodent studies are also indicated, particularly 
in the areas frequented by patient 1, as the original source 
of the infection remains unknown.
Discussion
Arenaviruses are negative-sense single-stranded RNA 
viruses, most of which cause chronic infection of rodents, 
with excretion of virus in urine. Humans become infected 
from contaminated food or household items. Several New 
World arenaviruses are associated with hemorrhagic fe-
vers in South America, including Junin, Machupo, Sabia, 
Guanarito, and Chapare viruses. Old World arenaviruses 
include the prototype member of the family, lymphocytic 
choriomeningitis virus, which has a worldwide distribution 
and is often associated with pet rodents. Clinical manifesta-
tions range from inapparent infection to severe meningoen-
cephalomyelitis in humans. Dandenong virus is an arenavi-
rus related to lymphocytic choriomeningitis virus (Figure 
3) that was recently isolated in Australia from patients who 
had received organ transplants from a deceased donor who 
had traveled in eastern Europe (7). Lassa fever virus is an 
Old World arenavirus associated with the multimammate 
mouse (Mastomys natalensis) that causes hemorrhagic fe-
ver, which affects large numbers of persons in West Africa. 
Imported cases of the disease have occurred in Europe, 
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Table. Summary of diagnostic RT-PCR and virus isolation studies on 5 novel arena virus–infected patients, southern Africa, 2008*
Patient no. Onset of illness Date sampled Day of illness sampled Sample type RT-PCR Virus isolation
1 Sep 2  Sep 12 11 Blood + +
2 Sep 21 Sep 25 5 Blood – +
2 Sep 21 Sep 29 9 Blood – +
2 Sep 21 Sep 30 10 Blood – +
2 Sep 21 Oct 9 12† Liver + +
3 Sep 23 Oct 3 11 Blood – +
3 Sep 23 Oct 9 13† Liver + +
4 Sep 27 Oct 6 10 Blood + +
5 Oct 9 Oct 10 2 Blood + +
*Chronology of testing samples differs from the order in which they were collected from patients. RT-PCR, reverse transcription–PCR; +, positive; –, 
negative. 
†Refers to day of illness on which the patient died. RESEARCH
North America, Asia, and South Africa (8; NICD, unpub. 
data). The distribution of the multimammate mouse and re-
lated species extends across much of sub-Saharan Africa. 
Old World arenaviruses not known to be pathogenic for 
humans include Ippy and Mobala viruses from the Cen-
tral African Republic and Morogoro virus from Tanzania 
(9). Arenaviruses have also been found in rodents in Mo-
zambique (Mopeia virus) and Zimbabwe (10,11) as well 
as  South  Africa  (NICD,  unpub.  data),  but  phylogenetic 
analysis  using  partial  nucleotide  sequence  data  indicate 
that these are distinct from the new virus described here, 
and none of these viruses have been associated with human 
disease in these 3 countries, despite sustained monitoring 
over 3 decades.
As  described  elsewhere  (5),  this  is  the  first  highly 
pathogenic arenavirus to be identified in Africa in 4 de-
cades. This outbreak serves as a warning that pathogenic 
arenaviruses could be more widely prevalent in Africa than 
presently realized and reinforces the need for strict screen-
ing of internationally transferred patients to ensure early 
recognition of infectious diseases and the maintenance of 
appropriate infection control precautions at all times.
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